News >

FDA Approves Durvalumab for Frontline Small Cell Lung Cancer

Gina Columbus @ginacolumbusonc
Published: Monday, Mar 30, 2020

The FDA has approved durvalumab (Imfinzi) for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) for use in combination with standard-of-care chemotherapy, including etoposide plus either carboplatin or cisplatin.1

Durvalumab is approved by the FDA for the treatment of patients with locally advanced, unresectable stage III non–small cell lung cancer who have not progressed following chemoradiotherapy. The PD-L1 inhibitor also has an FDA-approved indication for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy, or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.


  1. Imfinzi approved in the US for extensive-stage small cell lung cancer [news release]: AstraZeneca. Published March 30, 2020. Accessed March 30, 2020.
  2. L. Paz-Ares, Y. Chen, N. Reinmuth, et al. Overall survival with durvalumab plus etoposide-platinum in first-line extensive-stage SCLC: results from the CASPIAN study. Presented at: IASLC 20th World Conference on Lung Cancer; September 7-10, 2019; Barcelona, Spain. Abstract OA02.02.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication